August #38 : In the Hot Seat - by Dave Gilden

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Tales of the City

Ask Amelio

Petunias

The Mere Future

Record Time

Veronica

The American People

Switching Channels

Takin’ It to the Streets

Have A Ball

The Grass Is Greener

S.O.S.

To the Editor

Pass the AZT

Deadly Dad

Stuck in the Riddle

Survey Says...

Let’s Talk About Sex

Name Game

Vive la France!

Gets His Goat

Going Downtown? Dam It

Dr. Dementia

Voices Carry

Obits

And Now For Something Entirely Fiction

Tita Aida

Death Becomes Her

In the Hot Seat

Oh, Viagra!

You Can’t Take It With You

Clean and Sober

Know Your Writes

Pills, Chills and Thrills

TB or not TB

Move It!

Risky When Rushed

It’s All About the Journal

Heart of the Matter

Stink Balms

Angel and Insects

Pier 48

Say What



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

August 1998

In the Hot Seat

by Dave Gilden

Advocates have access, but industry sets the agenda

April saw a flare-up among AIDS activists as only a small, select group met with Glaxo Wellcome, while others (including ACT UPers on both coasts) were excluded from the confab. A national ad-hoc coalition had asked for a sit-down with the company to discuss an expanded-access program for its experimental protease inhibitor amprenavir. Glaxo agreed with surprising alacrity—and then proceeded to hand-pick participants, flying seven treatment wonks to its North Carolina offices on the company tab (I was patched in by phone at GMHC).

ACT UP/Golden Gate was especially miffed. In a letter circulated on the eve of the meeting, the Golden Gaters complained that the drug giant barred ACT UP because of its campaign (including a boycott and demos) last year for expanded access to its other new anti-HIV drug, abacavir. “We do not think that other community members  should attend a meeting where people with HIV who have long worked on expanded access are explicitly excluded,” the letter concluded.

Those who made Glaxo’s list complained, too—all the way to North Carolina. But once there, they showed their mettle: By meeting’s end, they had argued Glaxo out of its plan to limit access to small trials using amprenavir to rescue treatment failures. Instead, Glaxo promised to distribute the drug to anyone not benefiting from current regimens.  

This exchange had more positive effects than many such meetings that, taken together, mark the regression of treatment activism into uncoordinated lobbying. As community unity withers, a new breed of professional “advocate” has appeared, with the drug industry’s complicity and largely outside public view. Every big AIDS nonprofit has at least one such employee, not to mention a staff partially funded by pharmaceutical grants. And there are several unaffiliated players who also depend on drug money. So far, most of these advocates are modestly paid, hard-working ex-activists.

These industry-advocate meetings serve three main functions. They offer an advance peek at data from lab experiments and clinical trials, with the figures presented to portray a compound uniquely structured to avoid drug resistance and serious side effects. This spin usually turns out to be false later, when better information is available, but by then the hype is on.

Discussion also turns on the design of upcoming trials. Some activists are now so expert that they can advise the companies on how best to construct studies so as to recruit volunteers and collect useful data. Even when acrimonious, these pro-bono consultations are highly valued by the industry.

If convinced of a drug’s worth, advocates intercede with the FDA in favor of its approval. But in return, they demand certain quid pro quos. No. 1 on the list is expanded access—as with amprenavir. Campaigns for access to experimental drugs have a long and honorable history, but of late they have lost much of their urgency.

For now, protease regimens have stabilized many, and community-inspired changes at the FDA plus technological advances have greatly sped drug development. In place of tens of thousands receiving an experimental drug for years, current expanded access enrolls a few thousand for a few months before the FDA allows normal sales. These programs have become one more part of a drug’s premarketing buildup, and advocates’ best intentions pave the road to corporate profits. It would be easy to condemn treatment advocates for allowing themselves to be co-opted. Yet present relations mark a natural evolution wrought by the “give us more drugs now” activism of yore.

I can’t help but wish that the agenda at these get-togethers was set less by the companies and more by the community. If the times are no longer so desperate, there is surely opportunity to address the larger picture: Pharmaceutical research has given people with HIV a future chock-full of lab tests, pill taking and side effects. It’s a life, but one with enormous burdens that concern the drug industry not at all. The community spurred on the pace of drug development—it will have to work just as hard to win practical treatments accessible to all.




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    fokisi
    Long Beach
    California


    koffeeboss
    Tucson
    Arizona


    latinpozdallas
    Dallas
    Texas


    robert12
    Queens
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Is HIV/AIDS adequately portrayed in pop culture?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.